OnabotulinumtoxinA Therapy for Headache

Outcomes Following OnabotulinumtoxinA Treatment (N = 195)

2017 – 2018

HIT-6 = Headache Impact Test, PDI = Pain Disability Index, PHQ-9 = Patient Health Questionnaire, PROMIS = Patient Reported Outcome Measurement Information System

In 2017 and 2018, the outcomes of 195 headache patients who were treated with onabotulinumtoxinA were reviewed. More than 75% had improved or stable HIT-6 scores,¹ and ≥ 85% similarly reported improved or stable pain disability,² PROMIS pain,³ and/or depression scores.⁴

  1. Coeytaux RR, Kaufman JS, Chao R, Mann JD, Devellis RF. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol. 2006 Apr;59(4):374-380.

  2. Soer R, Reneman MF, Vroomen PC, Stegeman P, Coppes MH. Responsiveness and minimally clinically important change of the Pain Disability Index in patients with chronic back pain. Spine, 2012 Apr 15;37(8):711-715.

  3. Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009 Sep;18(7):873-880.

  4. Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care. 2004 Dec;42(12):1194-1201.